Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy

Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy Sivaprakasam Amsaveni https://orcid.org/0000-0001-9063-7141 Mahendran Radha https://orcid.org/0000-0003-0711-0336 Vidhya Chandrasekaran https://orcid.org/0000-0003-1175-3668 Dilip Kumar Chanchal https://orcid.org/0000-0002-8937-3748 Sojomon Mathew https://orcid.org/0000-0002-4442-9875 Mukesh Chandra Sharma https://orcid.org/0000-0003-0222-5273 Jailani Shiekmydeen https://orcid.org/0000-0002-4869-5839 Syed Salman Ali https://orcid.org/0000-0001-9163-3353

The immune system presents significant obstacles to gene therapy, which has limited its use in treating many illnesses. New approaches are needed to overcome these problems and improve the effectiveness of gene therapy. This study explores several techniques to immune regulation within gene therapy, a cutting-edge discipline that aims to optimise results by fine-tuning the immune response. We cover new ways to control the immune system and deliver therapeutic genes just where they are needed, including influencing immunological checkpoints, causing immunotolerance, and making smart use of immunomodulatory drugs. In addition, the study provides insight into new developments in the design of less immunogenic gene delivery vectors, which allow for the extension of transgene expression with minimal adverse immune reactions. In order to maximise the efficacy of gene-based therapies, this review analyses these novel approaches and gives a thorough overview of the present state of the art by addressing obstacles and pointing the way toward future developments in immune regulation. Not only does their integration provide new opportunities for the creation of safer and more effective gene treatments, but it also contains the key to overcome current obstacles.
08 2025 374 393 LiveAll1 1 10.2174/BSP_crossmark_policy eurekaselect.com true Peer Reviewed Single blind Checked with iThenticate 2024-01-19 2024-07-09 2024-07-26 2025-07-03 10.2174/0115665232305409240918040639 https://www.eurekaselect.com/234767/article https://www.eurekaselect.com/article/download?doi=10.2174/0115665232305409240918040639 https://www.eurekaselect.com/article/download?doi=10.2174/0115665232305409240918040639 https://www.eurekaselect.com/article/download?doi=10.2174/0115665232305409240918040639 https://www.eurekaselect.com/article/download?doi=10.2174/0115665232305409240918040639 https://www.eurekaselect.com/article/download?doi=10.2174/0115665232305409240918040639 https://www.eurekaselect.com/article/download?doi=10.2174/0115665232305409240918040639 https://www.eurekaselect.com/article/download?doi=10.2174/0115665232305409240918040639 https://www.eurekaselect.com/234767/article Mol Ther Shirley J.L. 28 709 2020 10.1016/j.ymthe.2020.01.001 Shirley J.L.; de Jong Y.P.; Terhorst C.; Herzog R.W.; Immune responses to viral gene therapy vectors. Mol Ther 2020,28(3),709-722 Genet Mol Biol Freitas M.V. 45 e20220046 2022 10.1590/1678-4685-gmb-2022-0046 Freitas M.V.; Frâncio L.; Haleva L.; Matte U.S.; Protection is not always a good thing: The immune system’s impact on gene therapy. Genet Mol Biol 2022,45(3) (suppl 1),e20220046 Nat Rev Immunol Pollard A.J. 21 83 2021 10.1038/s41577-020-00479-7 Pollard A.J.; Bijker E.M.; A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 2021,21(2),83-100 Semin Cancer Biol Vinay D.S. 35 S185 2015 10.1016/j.semcancer.2015.03.004 Vinay D.S.; Ryan E.P.; Pawelec G.; Talib W.H.; Stagg J.; Elkord E.; Lichtor T.; Decker W.K.; Whelan R.L.; Kumara H.M.C.S.; Signori E.; Honoki K.; Georgakilas A.G.; Amin A.; Helferich W.G.; Boosani C.S.; Guha G.; Ciriolo M.R.; Chen S.; Mohammed S.I.; Azmi A.S.; Keith W.N.; Bilsland A.; Bhakta D.; Halicka D.; Fujii H.; Aquilano K.; Ashraf S.S.; Nowsheen S.; Yang X.; Choi B.K.; Kwon B.S.; Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015,35(Suppl.),S185-S198 Perspect Clin Res Nair S. 1 146 2010 10.4103/2229-3485.71775 Nair S.; Personalized medicine: Striding from genes to medicines. Perspect Clin Res 2010,1(4),146-150 Adv Pharm Bull Razi Soofiyani S. 3 249 2013 Razi Soofiyani S.; Baradaran B.; Lotfipour F.; Kazemi T.; Mohammadnejad L.; Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull 2013,3(2),249-255 J Cell Physiol Das S.K. 230 259 2015 10.1002/jcp.24791 Das S.K.; Menezes M.E.; Bhatia S.; Wang X.Y.; Emdad L.; Sarkar D.; Fisher P.B.; Gene therapies for cancer: Strategies, challenges and successes. J Cell Physiol 2015,230(2),259-271 Signal Transduct Target Ther Bulcha J.T. 6 53 2021 10.1038/s41392-021-00487-6 Bulcha J.T.; Wang Y.; Ma H.; Tai P.W.L.; Gao G.; Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther 2021,6(1),53 Gene Ther Nayak S. 17 295 2010 10.1038/gt.2009.148 Nayak S.; Herzog R.W.; Progress and prospects: immune responses to viral vectors. Gene Ther 2010,17(3),295-304 Vaccines Travieso T. 7 1 2022 Travieso T.; Li J.; Mahesh S.; Mello J.D.F.R.E.; Blasi M.; The use of viral vectors in vaccine development. Vaccines 2022,7(1),1-10 Vaccines Mendonça S.A. 6 1 2021 Mendonça S.A.; Lorincz R.; Boucher P.; Curiel D.T.; Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. Vaccines 2021,6(1),1-14 Allergy Asthma Clin Immunol Marshall J.S. 14 49 2018 10.1186/s13223-018-0278-1 Marshall J.S.; Warrington R.; Watson W.; Kim H.L.; An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol 2018,14(S2)(Suppl. 2),49 Front Immunol Amarante-Mendes G.P. 9 2379 2018 10.3389/fimmu.2018.02379 Amarante-Mendes G.P.; Adjemian S.; Branco L.M.; Zanetti L.C.; Weinlich R.; Bortoluci K.R.; Pattern recognition receptors and the host cell death molecular machinery. Front Immunol 2018,9,2379 Clin Rev Allergy Immunol Bulut O. 63 499 2021 10.1007/s12016-021-08905-x Bulut O.; Kilic G.; Domínguez-Andrés J.; Immune memory in aging: A wide perspective covering microbiota, brain, metabolism, and epigenetics. Clin Rev Allergy Immunol 2021,63(3),499-529 Epidemiology of viral infections Burrell C.J. 185 2017 Burrell C.J.; Howard C.R.; Murphy F.A.; Epidemiology of viral infections 2017,185 Front Immunol Kranich J. 7 225 2016 10.3389/fimmu.2016.00225 Kranich J.; Krautler N.J.; How follicular dendritic cells shape the b-cell antigenome. Front Immunol 2016,7,225 Front Immunol Palm A.K.E. 10 1787 2019 10.3389/fimmu.2019.01787 Palm A.K.E.; Henry C.; Remembrance of things past: Long-term B cell memory after infection and vaccination. Front Immunol 2019,10,1787 Clin Exp Immunol James L.K. 210 230 2022 10.1093/cei/uxac091 James L.K.; B cells defined by immunoglobulin isotypes. Clin Exp Immunol 2022,210(3),230-239 Cell Cyster J.G. 177 524 2019 10.1016/j.cell.2019.03.016 Cyster J.G.; Allen C.D.C.; B cell responses - Cell interaction dynamics and decisions. Cell 2019,177(3),524-540 Br J Cancer Raskov H. 124 359 2021 10.1038/s41416-020-01048-4 Raskov H.; Orhan A.; Christensen J.P.; Gögenur I.; Cytotoxic CD8 T cells in cancer and cancer immunotherapy. Br J Cancer 2021,124(2),359-367 Mol Ther Goverdhana S. 12 189 2005 10.1016/j.ymthe.2005.03.022 Goverdhana S.; Puntel M.; Xiong W.; Zirger J.M.; Barcia C.; Curtin J.F.; Soffer E.B.; Mondkar S.; King G.D.; Hu J.; Sciascia S.A.; Candolfi M.; Greengold D.S.; Lowenstein P.R.; Castro M.G.; Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005,12(2),189-211 Adv Cancer Res Kumar A. 160 253 2023 10.1016/bs.acr.2023.03.005 Kumar A.; Das S.K.; Emdad L.; Fisher P.B.; Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy. Adv Cancer Res 2023,160,253-315 Transl Res Hackett P.B. 161 265 2013 10.1016/j.trsl.2012.12.005 Hackett P.B.; Largaespada D.A.; Switzer K.C.; Cooper L.J.N.; Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res 2013,161(4),265-283 ISRN Oncol Romano G. 2012 1 2012 10.5402/2012/616310 Romano G.; Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN Oncol 2012,2012,1-14 Front Immunol Ronzitti G. 11 670 2020 10.3389/fimmu.2020.00670 Ronzitti G.; Gross D.A.; Mingozzi F.; Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol 2020,11,670 Front Immunol Zhan W. 12 673699 2021 10.3389/fimmu.2021.673699 Zhan W.; Muhuri M.; Tai P.W.L.; Gao G.; Vectored immunotherapeutics for infectious diseases: Can rAAVs be the game changers for fighting transmissible pathogens? Front Immunol 2021,12,673699 Curr Opin Mol Ther Sack B.K. 11 493 2009 Sack B.K.; Herzog R.W.; Evading the immune response upon in vivo gene therapy with viral vectors. Curr Opin Mol Ther 2009,11(5),493-503 Mol Ther Methods Clin Dev Büning H. 12 248 2019 10.1016/j.omtm.2019.01.008 Büning H.; Srivastava A.; Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev 2019,12,248-265 Front Immunol Hamilton B.A. 12 675897 2021 10.3389/fimmu.2021.675897 Hamilton B.A.; Wright J.F.; Challenges posed by immune responses to AAV vectors: Addressing root causes. Front Immunol 2021,12,675897 J Virol Gurda B.L. 86 7739 2012 10.1128/JVI.00218-12 Gurda B.L.; Raupp C.; Popa-Wagner R.; Naumer M.; Olson N.H.; Ng R.; McKenna R.; Baker T.S.; Kleinschmidt J.A.; Agbandje-McKenna M.; Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J Virol 2012,86(15),7739-7751 Cell Raguram A. 185 2806 2022 10.1016/j.cell.2022.03.045 Raguram A.; Banskota S.; Liu D.R.; Therapeutic in vivo delivery of gene editing agents. Cell 2022,185(15),2806-2827 Hum Gene Ther Prasad S. 33 1228 2022 10.1089/hum.2022.138 Prasad S.; Dimmock D.P.; Greenberg B.; Walia J.S.; Sadhu C.; Tavakkoli F.; Lipshutz G.S.; Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: Current knowledge and approaches. Hum Gene Ther 2022,33(23-24),1228-1245 Semin Immunol Sasso E. 50 101430 2020 10.1016/j.smim.2020.101430 Sasso E.; D’Alise A.M.; Zambrano N.; Scarselli E.; Folgori A.; Nicosia A.; New viral vectors for infectious diseases and cancer. Semin Immunol 2020,50,101430 J Neuromuscul Dis Elangkovan N. 8 S303 2021 10.3233/JND-210678 Elangkovan N.; Dickson G.; Gene therapy for duchenne muscular dystrophy. J Neuromuscul Dis 2021,8(Suppl. 2),S303-S316 J Thromb Haemost Arruda V.R. 14 1121 2016 10.1111/jth.13331 Arruda V.R.; Samelson-Jones B.J.; Gene therapy for immune tolerance induction in hemophilia with inhibitors. J Thromb Haemost 2016,14(6),1121-1134 Front Immunol Slepicka P.F. 12 688460 2021 10.3389/fimmu.2021.688460 Slepicka P.F.; Yazdanifar M.; Bertaina A.; Harnessing mechanisms of immune tolerance to improve outcomes in solid organ transplantation: A review. Front Immunol 2021,12,688460 Cold Spring Harb Perspect Biol Xing Y. 4 a006957 2012 10.1101/cshperspect.a006957 Xing Y.; Hogquist K.A.; T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol 2012,4(6),a006957 Cell Sakaguchi S. 133 775 2008 10.1016/j.cell.2008.05.009 Sakaguchi S.; Yamaguchi T.; Nomura T.; Ono M.; Regulatory T cells and immune tolerance. Cell 2008,133(5),775-787 Transplantation of the Liver Ruiz R. 1354 2015 10.1016/B978-1-4557-0268-8.00097-X Ruiz R.; Kirk A.D.; Long-term toxicity of immunosuppressive therapy. Transplantation of the Liver 2015,1354 Immunology Taams L.S. 118 1 2006 10.1111/j.1365-2567.2006.02348.x Taams L.S.; Palmer D.B.; Akbar A.N.; Robinson D.S.; Brown Z.; Hawrylowicz C.M.; Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006,118(1),1-9 Front Bioeng Biotechnol Ewaisha R. 11 1138596 2023 10.3389/fbioe.2023.1138596 Ewaisha R.; Anderson K.S.; Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation. Front Bioeng Biotechnol 2023,11,1138596 AAPS J Wen H. 17 1327 2015 10.1208/s12248-015-9814-9 Wen H.; Jung H.; Li X.; Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. AAPS J 2015,17(6),1327-1340 Int J Genom Khan S. 2016 2405954 2016 10.1155/2016/2405954 Khan S.; Ullah M.W.; Siddique R.; Nabi G.; Manan S.; Yousaf M.; Role of recombinant DNA technology to improve life Int J Genom 2016,2016,2405954 Front Oncol Uddin F. 10 1387 2020 10.3389/fonc.2020.01387 Uddin F.; Rudin C.M.; Sen T.; CRISPR gene therapy: Applications, limitations, and implications for the future. Front Oncol 2020,10,1387 J Clin Diagn Res Ramamoorth M. 9 GE01 2015 10.7860/JCDR/2015/10443.5394 Ramamoorth M.; Narvekar A.; Non viral vectors in gene therapy- an overview. J Clin Diagn Res 2015,9(1),GE01-GE06 Adv Biomed Res Nayerossadat N. 1 27 2012 10.4103/2277-9175.98152 Nayerossadat N.; Maedeh T.; Ali P.; Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 2012,1(1),27 Pharmaceuticals (Basel) Shchaslyvyi A.Y. 16 1416 2023 10.3390/ph16101416 Shchaslyvyi A.Y.; Antonenko S.V.; Tesliuk M.G.; Telegeev G.D.; Current state of human gene therapy: Approved products and vectors. Pharmaceuticals (Basel) 2023,16(10),1416 Cell Res Zheng D. 30 492 2020 10.1038/s41422-020-0332-7 Zheng D.; Liwinski T.; Elinav E.; Interaction between microbiota and immunity in health and disease. Cell Res 2020,30(6),492-506 Nat Rev Immunol Kaech S.M. 2 251 2002 10.1038/nri778 Kaech S.M.; Wherry E.J.; Ahmed R.; Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002,2(4),251-262 Mol Ther Shayakhmetov D.M. 18 1422 2010 10.1038/mt.2010.124 Shayakhmetov D.M.; Di Paolo N.C.; Mossman K.L.; Recognition of virus infection and innate host responses to viral gene therapy vectors. Mol Ther 2010,18(8),1422-1429 Immunology Ahrends T. 154 582 2018 10.1111/imm.12941 Ahrends T.; Borst J.; The opposing roles of 4 T cells in anti-tumour immunity. Immunology 2018,154(4),582-592 Virol J Chinnasamy D. 3 14 2006 10.1186/1743-422X-3-14 Chinnasamy D.; Milsom M.D.; Shaffer J.; Neuenfeldt J.; Shaaban A.F.; Margison G.P.; Fairbairn L.J.; Chinnasamy N.; Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol J 2006,3(1),14 J Virol Methods Roy S. 141 14 2007 10.1016/j.jviromet.2006.11.022 Roy S.; Clawson D.S.; Lavrukhin O.; Sandhu A.; Miller J.; Wilson J.M.; Rescue of chimeric adenoviral vectors to expand the serotype repertoire. J Virol Methods 2007,141(1),14-21 Curr Protoc Microbiol Ahmed S.S. 14 6 2013 10.1002/9780471729259.mc14d06s29 Ahmed S.S.; Li J.; Godwin J.; Gao G.; Zhong L.; Gene transfer in the liver using recombinant adeno-associated virus. Curr Protoc Microbiol 2013,14(1),6 Cells Fogagnolo A. 11 424 2022 10.3390/cells11030424 Fogagnolo A.; Campo G.C.; Mari M.; Pompei G.; Pavasini R.; Volta C.A.; Spadaro S.; The underestimated role of platelets in severe infection a narrative review. Cells 2022,11(3),424 Front Immunol Gritsenko A. 11 565924 2020 10.3389/fimmu.2020.565924 Gritsenko A.; Yu S.; Martin-Sanchez F.; Diaz-del-Olmo I.; Nichols E.M.; Davis D.M.; Brough D.; Lopez-Castejon G.; Priming is dispensable for NLRP3 inflammasome activation in human monocytes in vitro. Front Immunol 2020,11,565924 Vaccines (Basel) Kuzmich N. 5 34 2017 10.3390/vaccines5040034 Kuzmich N.; Sivak K.; Chubarev V.; Porozov Y.; Savateeva-Lyubimova T.; Peri F.; TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines (Basel) 2017,5(4),34 Front Immunol Ertl H.C.J. 13 975803 2022 10.3389/fimmu.2022.975803 Ertl H.C.J.; Immunogenicity and toxicity of AAV gene therapy. Front Immunol 2022,13,975803 Br J Pharmacol Barnes P.J. 148 245 2006 10.1038/sj.bjp.0706736 Barnes P.J.; How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006,148(3),245-254 J Transplant Mukherjee S. 2009 1 2009 10.1155/2009/701464 Mukherjee S.; Mukherjee U.; A comprehensive review of immunosuppression used for liver transplantation. J Transplant 2009,2009,1-20 Pharmaceutics Niemann B. 14 2551 2022 10.3390/pharmaceutics14122551 Niemann B.; Puleo A.; Stout C.; Markel J.; Boone B.A.; Biologic functions of hydroxychloroquine in disease: From COVID-19 to cancer. Pharmaceutics 2022,14(12),2551 Mol Cell Endocrinol Coutinho A.E. 335 2 2011 10.1016/j.mce.2010.04.005 Coutinho A.E.; Chapman K.E.; The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011,335(1),2-13 PM R Mitra R. 3 466 2011 10.1016/j.pmrj.2011.02.017 Mitra R.; Adverse effects of corticosteroids on bone metabolism: a review. PM R 2011,3(5),466-471 Trends Immunol Pollizzi K.N. 36 13 2015 10.1016/j.it.2014.11.005 Pollizzi K.N.; Powell J.D.; Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol 2015,36(1),13-20 Nat Rev Nephrol Agrawal S. 14 57 2018 10.1038/nrneph.2017.155 Agrawal S.; Zaritsky J.J.; Fornoni A.; Smoyer W.E.; Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018,14(1),57-70 Eur J Pharmacol Paniri A. 886 173454 2020 10.1016/j.ejphar.2020.173454 Paniri A.; Hosseini M.M.; Rasoulinejad A.; Akhavan-Niaki H.; Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations. Eur J Pharmacol 2020,886,173454 Med Hypothesis Discov Innov Ophthalmol Espandar G. 5 41 2016 Espandar G.; Moghimi J.; Ghorbani R.; Pourazizi M.; Seiri M.A.; Khosravi S.; Retinal toxicity in patients treated with hydroxychloroquine: A cross-sectional study. Med Hypothesis Discov Innov Ophthalmol 2016,5(2),41-46 Nat Rev Cancer Melero I. 7 95 2007 10.1038/nrc2051 Melero I.; Hervas-Stubbs S.; Glennie M.; Pardoll D.M.; Chen L.; Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007,7(2),95-106 Ann N Y Acad Sci Donnelly R.P. 1182 1 2009 10.1111/j.1749-6632.2009.05382.x Donnelly R.P.; Young H.A.; Rosenberg A.S.; An overview of cytokines and cytokine antagonists as therapeutic agents. Ann N Y Acad Sci 2009,1182(1),1-13 Nat Rev Cancer Vanneman M. 12 237 2012 10.1038/nrc3237 Vanneman M.; Dranoff G.; Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012,12(4),237-251 J Transplant Saso S. 2012 1 2012 10.1155/2012/134936 Saso S.; Logan K.; Abdallah Y.; Louis L.S.; Ghaem-Maghami S.; Smith J.R.; Del Priore G.; Use of cyclosporine in uterine transplantation. J Transplant 2012,2012,1-11 J Korean Assoc Oral Maxillofac Surg Lee H. 49 311 2023 10.5125/jkaoms.2023.49.6.311 Lee H.; Myoung H.; Kim S.M.; Review of two immunosuppressants: tacrolimus and cyclosporine. J Korean Assoc Oral Maxillofac Surg 2023,49(6),311-323 Nat Nanotechnol Burke J.A. 17 319 2022 10.1038/s41565-021-01048-2 Burke J.A.; Zhang X.; Bobbala S.; Frey M.A.; Bohorquez Fuentes C.; Freire Haddad H.; Allen S.D.; Richardson R.A.K.; Ameer G.A.; Scott E.A.; Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability. Nat Nanotechnol 2022,17(3),319-330 Expert Opin Investig Drugs Behrend M. 7 1509 1998 10.1517/13543784.7.9.1509 Behrend M.; Mycophenolate mofetil (Cellcept). Expert Opin Investig Drugs 1998,7(9),1509-1519 Int J Exp Pathol Molyneux G. 89 138 2008 10.1111/j.1365-2613.2008.00575.x Molyneux G.; Gibson F.M.; Chen C.M.; Marway H.K.; McKeag S.; Mifsud C.V.J.; Pilling A.M.; Whayman M.J.; Turton J.A.; The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse. Int J Exp Pathol 2008,89(2),138-158 Int J Mol Sci Ferrara G. 20 444 2019 10.3390/ijms20020444 Ferrara G.; Petrillo M.G.; Giani T.; Marrani E.; Filippeschi C.; Oranges T.; Simonini G.; Cimaz R.; Clinical use and molecular action of corticosteroids in the pediatric age. Int J Mol Sci 2019,20(2),444 Front Med (Lausanne) Lombardi Y. 9 942665 2022 10.3389/fmed.2022.942665 Lombardi Y.; François H.; Belatacept in kidney transplantation: What are the true benefits? A systematic review. Front Med (Lausanne) 2022,9,942665 Exp Ther Med Yao X. 11 2541 2016 10.3892/etm.2016.3238 Yao X.; Weng G.; Wei J.; Gao W.; Basiliximab induction in kidney transplantation with donation after cardiac death donors. Exp Ther Med 2016,11(6),2541-2546 Gut Van Assche G. 55 1568 2006 10.1136/gut.2005.089854 Van Assche G.; Sandborn W.J.; Feagan B.G.; Salzberg B.A.; Silvers D.; Monroe P.S.; Pandak W.M.; Anderson F.H.; Valentine J.F.; Wild G.E.; Geenen D.J.; Sprague R.; Targan S.R.; Rutgeerts P.; Vexler V.; Young D.; Shames R.S.; Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006,55(11),1568-1574 J Neurol Chisari C.G. 269 159 2022 10.1007/s00415-020-10362-z Chisari C.G.; Sgarlata E.; Arena S.; Toscano S.; Luca M.; Patti F.; Rituximab for the treatment of multiple sclerosis: a review. J Neurol 2022,269(1),159-183 Clin Exp Immunol Li Z. 194 295 2018 10.1111/cei.13208 Li Z.; Richards S.; Surks H.K.; Jacobs A.; Panzara M.A.; Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol 2018,194(3),295-314 Am J Transl Res Kwon Y. 11 6422 2019 Kwon Y.; Lee K.W.; Park H.; Son J.K.; Lee J.; Hong J.; Park J.B.; Kim S.J.; Comparative study of human and cynomolgus T-cell depletion with rabbit anti-thymocyte globulin (rATG) treatment-for dose adjustment in a non-human primate kidney transplantation model. Am J Transl Res 2019,11(10),6422-6432 Ann Transplant Samsel R. 4 37 1999 Samsel R.; Perioperative single high dose ATG-Fresenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation--preliminary results. Ann Transplant 1999,4(2),37-39 J Clin Rheumatol Bird P. 25 115 2019 10.1097/RHU.0000000000000786 Bird P.; Bensen W.; El-Zorkany B.; Kaine J.; Manapat-Reyes B.H.; Pascual-Ramos V.; Witcombe D.; Soma K.; Zhang R.; Thirunavukkarasu K.; Tofacitinib 5 mg twice daily in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. J Clin Rheumatol 2019,25(3),115-126 Pharmacol Ther Huwiler A. 185 34 2018 10.1016/j.pharmthera.2017.11.001 Huwiler A.; Zangemeister-Wittke U.; The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. Pharmacol Ther 2018,185,34-49 Signal Transduct Target Ther Qin S. 7 166 2022 10.1038/s41392-022-01007-w Qin S.; Tang X.; Chen Y.; Chen K.; Fan N.; Xiao W.; Zheng Q.; Li G.; Teng Y.; Wu M.; Song X.; mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022,7(1),166 Front Immunol Strzelec M. 14 1127704 2023 10.3389/fimmu.2023.1127704 Strzelec M.; Detka J.; Mieszczak P.; Sobocińska M.K.; Majka M.; Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol 2023,14,1127704 Front Med (Lausanne) Hosseinalizadeh H. 10 1244298 2023 10.3389/fmed.2023.1244298 Hosseinalizadeh H.; Rabiee F.; Eghbalifard N.; Rajabi H.; Klionsky D.J.; Rezaee A.; Regulating the regulatory T cells as cell therapies in autoimmunity and cancer. Front Med (Lausanne) 2023,10,1244298 Front Immunol Bluestone J.A. 14 1166135 2023 10.3389/fimmu.2023.1166135 Bluestone J.A.; McKenzie B.S.; Beilke J.; Ramsdell F.; Opportunities for Treg cell therapy for the treatment of human disease. Front Immunol 2023,14,1166135 Charles A Janeway J. 2001 Charles A Janeway J.; Travers P.; Walport M.; Shlomchik M.J.; The components of the immune system. Available from: https://www.healio.com/hematology-oncology/learn-immuno-oncology/the-immune-system/components-of-the-immune-system(accessed on 27-8-2024)2001 Front Immunol Zhao L. 10 2250 2019 10.3389/fimmu.2019.02250 Zhao L.; Cao Y.J.; Engineered T.; Engineered T cell therapy for cancer in the clinic. Front Immunol 2019,10,2250 Oncotarget Xia A.L. 8 90521 2017 10.18632/oncotarget.19361 Xia A.L.; Wang X.C.; Lu Y.J.; Lu X.J.; Sun B.; Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. Oncotarget 2017,8(52),90521-90531 Biomedicines Tong C. 11 1673 2023 10.3390/biomedicines11061673 Tong C.; Liang Y.; Han X.; Zhang Z.; Zheng X.; Wang S.; Song B.; Research progress of dendritic cell surface receptors and targeting. Biomedicines 2023,11(6),1673 Immunotherapy Sabado R.L. 2 37 2010 10.2217/imt.09.43 Sabado R.L.; Bhardwaj N.; Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2010,2(1),37-56 Int J Mol Sci Hirayama D. 19 92 2017 10.3390/ijms19010092 Hirayama D.; Iida T.; Nakase H.; The phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis. Int J Mol Sci 2017,19(1),92 Nat Rev Drug Discov Mantovani A. 21 799 2022 10.1038/s41573-022-00520-5 Mantovani A.; Allavena P.; Marchesi F.; Garlanda C.; Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 2022,21(11),799-820 Front Immunol Abel A.M. 9 1869 2018 10.3389/fimmu.2018.01869 Abel A.M.; Yang C.; Thakar M.S.; Malarkannan S.; Natural killer cells: Development, maturation, and clinical utilization. Front Immunol 2018,9,1869 2006 Immunomodulation C on ND in the S of AT. Promising Approaches to the Development of Immunomodulation for the Treatment of Infectious Diseases. 2006 Nat Rev Drug Discov Sahin U. 13 759 2014 10.1038/nrd4278 Sahin U.; Karikó K.; Türeci Ö.; mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov 2014,13(10),759-780 Clin Cancer Res Beatty G.L. 21 687 2015 10.1158/1078-0432.CCR-14-1860 Beatty G.L.; Gladney W.L.; Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015,21(4),687-692 Biomaterials and Biosystems Khatun S. 9 100073 2023 10.1016/j.bbiosy.2023.100073 Khatun S.; Putta C.L.; Hak A.; Rengan A.K.; Immunomodulatory nanosystems: An emerging strategy to combat viral infections. Biomaterials and Biosystems 2023,9,100073 Med Oral Patol Oral Cir Bucal Bascones-Martinez A. 19 e24 2014 10.4317/medoral.19087 Bascones-Martinez A.; Mattila R.; Gomez-Font R.; Meurman J.H.; Immunomodulatory drugs: Oral and systemic adverse effects. Med Oral Patol Oral Cir Bucal 2014,19(1),e24-e31 Front Bioeng Biotechnol Lin G. 11 1242126 2023 10.3389/fbioe.2023.1242126 Lin G.; Wang J.; Yang Y.G.; Zhang Y.; Sun T.; Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance. Front Bioeng Biotechnol 2023,11,1242126 BioTech Tavakoli K. 10 14 2021 10.3390/biotech10030014 Tavakoli K.; Pour-Aboughadareh A.; Kianersi F.; Poczai P.; Etminan A.; Shooshtari L.; Applications of CRISPR-Cas9 as an advanced genome editing system in life sciences. BioTech 2021,10(3),14 Hum Gene Ther Wang D. 26 432 2015 10.1089/hum.2015.087 Wang D.; Mou H.; Li S.; Li Y.; Hough S.; Tran K.; Li J.; Yin H.; Anderson D.G.; Sontheimer E.J.; Weng Z.; Gao G.; Xue W.; Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther 2015,26(7),432-442 OncoImmunology Ajina R. 8 e1577127 2019 10.1080/2162402X.2019.1577127 Ajina R.; Zamalin D.; Zuo A.; Moussa M.; Catalfamo M.; Jablonski S.A.; Weiner L.M.; SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice. OncoImmunology 2019,8(5),e1577127 Nat Med Charlesworth C.T. 25 249 2019 10.1038/s41591-018-0326-x Charlesworth C.T.; Deshpande P.S.; Dever D.P.; Camarena J.; Lemgart V.T.; Cromer M.K.; Vakulskas C.A.; Collingwood M.A.; Zhang L.; Bode N.M.; Behlke M.A.; Dejene B.; Cieniewicz B.; Romano R.; Lesch B.J.; Gomez-Ospina N.; Mantri S.; Pavel-Dinu M.; Weinberg K.I.; Porteus M.H.; Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 2019,25(2),249-254 Clin Diagn Lab Immunol Boesen A. 12 1223 2005 Boesen A.; Sundar K.; Coico R.; Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T- lymphocyte responses in HLA-A2.1 transgenic mice. Clin Diagn Lab Immunol 2005,12(10),1223-1230 Technology (Singap) Krzyszczyk P. 6 79 2018 10.1142/S2339547818300020 Krzyszczyk P.; Acevedo A.; Davidoff E.J.; Timmins L.M.; Marrero-Berrios I.; Patel M.; White C.; Lowe C.; Sherba J.J.; Hartmanshenn C.; O’Neill K.M.; Balter M.L.; Fritz Z.R.; Androulakis I.P.; Schloss R.S.; Yarmush M.L.; The growing role of precision and personalized medicine for cancer treatment. Technology (Singap) 2018,6(03n04),79-100 Front Oncol Goswami R. 9 297 2019 10.3389/fonc.2019.00297 Goswami R.; Subramanian G.; Silayeva L.; Newkirk I.; Doctor D.; Chawla K.; Chattopadhyay S.; Chandra D.; Chilukuri N.; Betapudi V.; Gene therapy leaves a vicious cycle. Front Oncol 2019,9(APR),297 Int J Mol Sci Al-Tashi Q. 24 7781 2023 10.3390/ijms24097781 Al-Tashi Q.; Saad M.B.; Muneer A.; Qureshi R.; Mirjalili S.; Sheshadri A.; Le X.; Vokes N.I.; Zhang J.; Wu J.; Machine learning models for the identification of prognostic and predictive cancer biomarkers: A systematic review. Int J Mol Sci 2023,24(9),7781 Mol Ther Methods Clin Dev Kumar S.R.P. 3 16034 2016 10.1038/mtm.2016.34 Kumar S.R.P.; Markusic D.M.; Biswas M.; High K.A.; Herzog R.W.; Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016,3,16034 Int J Mol Sci Castaman G. 23 10228 2022 10.3390/ijms231810228 Castaman G.; Di Minno G.; De Cristofaro R.; Peyvandi F.; The arrival of gene therapy for patients with hemophilia A. Int J Mol Sci 2022,23(18),10228 Cells Chen G. 11 2964 2022 10.3390/cells11192964 Chen G.; Wei T.; Yang H.; Li G.; Li H.; CRISPR-based therapeutic gene editing for duchenne muscular dystrophy: Advances, challenges and perspectives. Cells 2022,11(19),2964 Theranostics Liu Z. 12 6273 2022 10.7150/thno.76854 Liu Z.; Zhou Z.; Dang Q.; Xu H.; Lv J.; Li H.; Han X.; Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics 2022,12(14),6273-6290 Med Res Rev Zhou H. 24 748 2004 10.1002/med.20009 Zhou H.; Liu D.; Liang C.; Challenges and strategies: The immune responses in gene therapy. Med Res Rev 2004,24(6),748-761 Nat Biotechnol Rohner E. 40 1586 2022 10.1038/s41587-022-01491-z Rohner E.; Yang R.; Foo K.S.; Goedel A.; Chien K.R.; Unlocking the promise of mRNA therapeutics. Nat Biotechnol 2022,40(11),1586-1600 Signal Transduct Target Ther Li H. 5 1 2020 10.1038/s41392-019-0089-y Li H.; Yang Y.; Hong W.; Huang M.; Wu M.; Zhao X.; Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther 2020,5(1),1-23 Fertil Steril Goetz L.H. 109 952 2018 10.1016/j.fertnstert.2018.05.006 Goetz L.H.; Schork N.J.; Personalized medicine: motivation, challenges, and progress. Fertil Steril 2018,109(6),952-963 Mol Ther Methods Clin Dev Colella P. 8 87 2018 10.1016/j.omtm.2017.11.007 Colella P.; Ronzitti G.; Mingozzi F.; Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev 2018,8,87-104 Nat Rev Drug Discov Mitchell M.J. 20 101 2021 10.1038/s41573-020-0090-8 Mitchell M.J.; Billingsley M.M.; Haley R.M.; Wechsler M.E.; Peppas N.A.; Langer R.; Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021,20(2),101-124 Int J Mol Sci Rulten S.L. 24 12613 2023 10.3390/ijms241612613 Rulten S.L.; Grose R.P.; Gatz S.A.; Jones J.L.; Cameron A.J.M.; The future of precision oncology. Int J Mol Sci 2023,24(16),12613 Front Immunol Pavlovic K. 11 570672 2020 10.3389/fimmu.2020.570672 Pavlovic K.; Tristán-Manzano M.; Maldonado-Pérez N.; Cortijo-Gutierrez M.; Sánchez-Hernández S.; Justicia-Lirio P.; Carmona M.D.; Herrera C.; Martin F.; Benabdellah K.; Using gene editing approaches to fine-tune the immune system. Front Immunol 2020,11,570672 Biomed Technol Elumalai K. 5 109 2024 10.1016/j.bmt.2023.09.001 Elumalai K.; Srinivasan S.; Shanmugam A.; Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Technol 2024,5,109-122 Front Bioeng Biotechnol Rittiner J. 10 1035543 2022 10.3389/fbioe.2022.1035543 Rittiner J.; Cumaran M.; Malhotra S.; Kantor B.; Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs. Front Bioeng Biotechnol 2022,10,1035543 Exp Mol Med Choi E.H. 55 1678 2023 10.1038/s12276-023-01057-2 Choi E.H.; Suh S.; Sears A.E.; Hołubowicz R.; Kedhar S.R.; Browne A.W.; Palczewski K.; Genome editing in the treatment of ocular diseases. Exp Mol Med 2023,55(8),1678-1690 Science Dunbar CE 359 2018 10.1126/science.aan4672 Dunbar CE; High KA; Joung JK; Kohn DB; Ozawa K; Sadelain M; Gene therapy comes of age. Science 2018,359(6372) Biomed Rep Mathur S 7 3 2017 10.3892/br.2017.922 Mathur S; Sutton J; Personalized medicine could transform healthcare. Biomed Rep 2017,7(1),3-5 Toussaint J 2010 Toussaint J; Gerard R; On the mend: Revolutionizing healthcare to save lives and transform the industry. 2010 Front Genome Editing Papanikolaou E 3 618346 2021 10.3389/fgeed.2021.618346 Papanikolaou E; Bosio A; The promise and the hope of gene therapy. Front Genome Editing 2021,3,618346 Curr Gene Ther Chanchal DK 24 193 2024 10.2174/0115665232275754231204072320 Chanchal DK; Chaudhary JS; Kumar P; Agnihotri N; Porwal P; CRISPR-based therapies: Revolutionizing drug development and precision medicine. Curr Gene Ther 2024,24(3),193-207 Expert Opin Drug Delivery Hopkins C 19 1337 2022 10.1080/17425247.2022.2112569 Hopkins C; Javius-Jones K; Wang Y; Hong H; Hu Q; Hong S; Combinations of chemo-, immuno-, and gene therapies using nanocarriers as a multifunctional drug platform. Expert Opin Drug Delivery 2022,19(10),1337-1349 J Drug Deliv Sci Technol Sahu T 63 102487 2021 10.1016/j.jddst.2021.102487 Sahu T; Ratre YK; Chauhan S; Bhaskar LV; Nair MP; Verma HK; Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. J Drug Deliv Sci Technol 2021,63,102487 J Intern Med Wang L 278 369 2015 10.1111/joim.12395 Wang L; Wang FS; Gershwin ME; Human autoimmune diseases: A comprehensive update. J Intern Med 2015,278(4),369-395 Adv Drug Deliv Rev Look M 62 378 2010 10.1016/j.addr.2009.11.011 Look M; Bandyopadhyay A; Blum JS; Fahmy TM; Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev 2010,62(4-5),378-393